Aspirin

Among patients hospitalized with moderate COVID-19, those who received aspirin on the first day of hospitalization had a significantly lower risk for 28-day mortality than those who did not, according to a recent observational cohort study.

Compared with no antiplatelet therapy, aspirin and P2Y12 inhibitors did not improve the number of organ support-free days in critically ill patients with COVID-19, according to results of the REMAP-CAP trial published in JAMA.

In a post hoc subgroup analysis of the ASPREE trial, those taking aspirin before the trial who were assigned placebo did not experience serious benefits or harms, researchers reported.

Compared with white patients, Black patients had lower odds of receiving statins for secondary cardiovascular disease prevention after kidney transplant.

In vitro and in vivo evidence has suggested that aspirin may have an antitumor effect, and several studies revealed longer survival in patients with breast cancer who used aspirin regularly compared with nonusers, according to researchers.

Use of aspirin failed to prolong invasive DFS among patients with breast cancer, according to results of a randomized phase 3 study presented during the ASCO Plenary Series.

Frequent use of over-the-counter analgesics, including moderate-dose aspirin, NSAIDs and acetaminophen, were associated with an increased risk for tinnitus among women, according to findings in the Journal of General Internal Medicine.

Pregnant women at highest risk for developing preeclampsia, such as those with diabetes and hypertension, are not routinely prescribed aspirin as recommended by guidelines, according to a population-based study.

Healio and Cardiology Today have aggregated a list of the most-read news in cardiology of 2021.

Last week’s top story in cardiology was about the FDA approval of Leqvio for LDL lowering. According to the manufacturer, the drug is administered twice a year after the initial dose and a follow-up dose at 3 months.